tiprankstipranks
Trending News
More News >
Aligos Therapeutics (ALGS)
NASDAQ:ALGS
Advertisement

Aligos Therapeutics (ALGS) AI Stock Analysis

Compare
230 Followers

Top Page

ALGS

Aligos Therapeutics

(NASDAQ:ALGS)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 4o)
Rating:45Neutral
Price Target:
$9.50
▲(1.50% Upside)
Aligos Therapeutics' overall stock score is primarily impacted by its poor financial performance and valuation, reflecting ongoing losses and cash flow challenges. While technical analysis shows some short-term strength, the long-term outlook remains weak.
Positive Factors
Proprietary Technology Platforms
The company's proprietary technology platforms provide a competitive edge in drug discovery, potentially leading to innovative therapies and partnerships.
Low Leverage
Low leverage enhances financial stability, providing flexibility to invest in R&D and withstand market fluctuations, crucial for long-term growth.
High Gross Profit Margins
High gross margins indicate efficient cost management in production, allowing more resources to be allocated to R&D and strategic initiatives.
Negative Factors
Negative Revenue Growth
Declining revenue growth suggests challenges in market expansion and product adoption, potentially impacting future profitability and competitiveness.
Consistent Losses
Persistent losses indicate operational inefficiencies and financial strain, which could hinder the company's ability to invest in growth opportunities.
Negative Cash Flow
Negative cash flow challenges the company's ability to fund operations and invest in R&D, potentially limiting long-term growth and innovation.

Aligos Therapeutics (ALGS) vs. SPDR S&P 500 ETF (SPY)

Aligos Therapeutics Business Overview & Revenue Model

Company DescriptionAligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
How the Company Makes MoneyAligos Therapeutics generates revenue through several key streams. Primarily, the company engages in research and development collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments based on the achievement of specific clinical or regulatory objectives, and royalties on future sales of products developed from these partnerships. Additionally, Aligos may receive funding from government grants or awards aimed at supporting innovative research in the biotech space. The company may also generate revenue through the licensing of its proprietary technologies or drug candidates to other firms in exchange for fees and royalties, enhancing its financial stability and growth prospects.

Aligos Therapeutics Financial Statement Overview

Summary
Aligos Therapeutics faces significant challenges in profitability, with consistent losses and negative cash flows, typical for an early-stage biotech firm focusing on research and development. The company's balance sheet is relatively robust with low leverage, providing stability. However, the ongoing cash burn rate and negative profitability metrics pose risks that need to be managed strategically.
Income Statement
35
Negative
Aligos Therapeutics shows a volatile revenue pattern with a decline to $3.27M in TTM from $15.53M in 2023. Despite improving gross profit margins, ongoing losses with a net profit margin of -1628% in TTM highlight persistent challenges in achieving profitability. The EBIT and EBITDA margins also remain negative, indicating operational inefficiencies.
Balance Sheet
45
Neutral
The balance sheet indicates a relatively stable equity position with stockholders' equity at $116.45M, although the negative net income affects ROE. The debt-to-equity ratio of 0.07 suggests low leverage, which is favorable, but the negative equity in previous years is a concern. The equity ratio stands at 77%, reflecting a strong asset base.
Cash Flow
30
Negative
Cash flow analysis reveals negative operating cash flow of -$78.91M, with free cash flow remaining negative at -$79.01M. However, strong financing cash flow at $102.12M in TTM supports liquidity. The operating cash flow to net income ratio shows inefficiency in converting net income to cash, a risk for future operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.17M3.94M15.53M13.91M4.36M0.00
Gross Profit2.24M3.94M12.46M10.23M-99.79M-3.33M
EBITDA-73.51M-89.15M-85.06M-93.91M-124.54M-105.06M
Net Income-74.18M-131.21M-87.68M-96.05M-128.33M-108.54M
Balance Sheet
Total Assets134.71M70.09M151.53M146.69M235.37M265.30M
Cash, Cash Equivalents and Short-Term Investments123.06M56.94M135.70M125.83M190.73M243.51M
Total Debt6.88M8.38M11.14M12.57M14.46M13.01M
Total Liabilities32.84M99.07M59.45M42.79M50.64M45.26M
Stockholders Equity101.87M-28.97M92.08M103.90M184.73M220.04M
Cash Flow
Free Cash Flow-75.12M-80.87M-79.02M-80.33M-116.55M-76.33M
Operating Cash Flow-74.92M-80.74M-79.00M-79.39M-115.66M-74.26M
Investing Cash Flow-53.12M-18.28M44.98M-26.29M3.02M32.76M
Financing Cash Flow101.66M355.00K88.33M164.00K78.68M192.35M

Aligos Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price9.36
Price Trends
50DMA
9.32
Positive
100DMA
8.04
Positive
200DMA
14.26
Negative
Market Momentum
MACD
0.10
Positive
RSI
46.04
Neutral
STOCH
52.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALGS, the sentiment is Negative. The current price of 9.36 is below the 20-day moving average (MA) of 10.32, above the 50-day MA of 9.32, and below the 200-day MA of 14.26, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 46.04 is Neutral, neither overbought nor oversold. The STOCH value of 52.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALGS.

Aligos Therapeutics Risk Analysis

Aligos Therapeutics disclosed 91 risk factors in its most recent earnings report. Aligos Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Aligos Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
50
Neutral
347.25M-2.111542.93%-40.16%78.28%
45
Neutral
$66.13M-87.74%-60.16%
45
Neutral
38.80M-0.53-133.86%61.15%54.71%
41
Neutral
35.16M-0.8861.18%
35
Underperform
42.67M-1.0254.85%
30
Underperform
30.51M-2.0231.09%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ALGS
Aligos Therapeutics
9.36
1.32
16.42%
TVRD
Tvardi Therapeutics
36.81
25.83
235.25%
ANVS
Annovis Bio
2.13
-5.97
-73.70%
GBIO
Generation Bio
5.72
-18.58
-76.46%
PYPD
PolyPid
3.37
-0.25
-6.91%
NRSN
Neurosense Therapeutics Ltd.
1.18
-0.10
-7.81%

Aligos Therapeutics Corporate Events

Shareholder Meetings
Aligos Therapeutics Approves Major Amendments at Annual Meeting
Neutral
Jun 26, 2025

On June 25, 2025, Aligos Therapeutics, Inc. held its Annual Meeting of Stockholders where significant amendments to the company’s Certificate of Incorporation were approved. These amendments included increasing the number of authorized shares of voting common stock from 20 million to 100 million and non-voting common stock from 800,000 to 15.8 million. These changes, effective immediately upon filing with the Secretary of State of Delaware, are expected to impact the company’s capital structure significantly. Additionally, stockholders voted on five proposals, including electing three Class II directors and ratifying Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ALGS) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Aligos Therapeutics stock, see the ALGS Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 19, 2025